In the course of evolution, the immune system has developed sophisticated mechanisms to identify and eliminate invading pathogens and degenerate cells, thereby preventing infection and tumor occurrence. When these mechanisms are ineffective or somehow bypassed, tumors or chronic infections may form. Clarifying the processes leading to ineffective immune defense is the central goal of the
The Antibody Engineering and Therapeutics conference will take place December 11th-15th 2017 at the Manchester Grand Hyatt in San Diego, California.
Mainz, November 24, 2017 – The University Clinic of Goethe University in Frankfurt is hosting a seminar as part of the German Society for Immunology’s Translational Immunology series. In this context, Sebastian Kreiter will be speaking on “Neo-antigen vaccination in cancer – translating science into survival.” Dr. Kreiter’s presentation will take place on Thursday, 30.
The Berlin Institute of Health, together with the Charité Universitätsmedizin Berlin, Max Delbrück Center for Molecule Medicine and Tagesspiegel, will host the second Future Medicine: Innovation in Health Science meeting on 7th November.
Mainz, October 27, 2017 – EMBL’s Cancer Genomics Conference offers a fabulous opportunity to keep up to date with the rapidly progressing area of cancer genomics. Presentations cover the latest from cancer genome projects, cancer functional genomics, systems biology, cancer immunogenomics and epigenomics, cancer mouse models and the translation and clinical impact of scientific results.
Mainz, 2017-10-25 – TRON scientific advisor Prof. Dr. Dr. Cornelis J. Melief, Leiden, Netherlands, will be awarded with the degree of an honorary medical doctor. Melief will be awarded for his lifetime achievements as a pioneer of tumor immunology, as well as for his commitment and deserts regarding immunological research in Mainz. Further information about
The topic of this year’s EFIS-EJI Ruggero-Ceppellini Advanced School of Immunology is “Tumour Immunology: from tissue microenvironment to immunotherapy.”
Was versprechen neuartige personalisierte Krebsimmuntherapien? Wie können Patienten von Ihnen profitieren, und welche Risiken bergen die Behandlungen? Zwei neue Ansätze in der Krebsimmuntherapie sind die CAR-T-Methode und die so genannten Neoantigen-Vakzine. Beide werden gerade getestet und sind sehr vielversprechend. Der regionale Radiosender SWR2 sendete hierzu einen Radiobeitrag in seinem Programm. Einen Mitschnitt sowie ein Transkript
The National Cancer Institute’s Center of Excellence in Immunogy sponsors a two-day symposium with the theme “Cancer Immunology and Immunotherapy: From Conception to Delivery”.
The Institute for Molecular Life Sciences at Radboud University Medical Center (RIMLS) will host a mini-symposium entitled “Chemical Immunology”.
The 12th Mainz Clinical Pathology Seminar will assemble experts from the basic scientific, clinical, biopharmaceutical and pathological fields to give an overview of the exciting developments in cancer immunotherapies.
The 1st Crick International Cancer Conference will bring together leading cancer scientists from all over the world to discuss the latest findings in cancer metabolism, the tumor microenvironment, and how the cancer genotype changes over time.